Leerink downgraded AlloVir to Market Perform from Outperform with a price target of $1, down from $14, after the company announced discontinuation of its three Phase 3 studies for lead asset posoleucel based on pre-planned futility analyses by the Data Safety Monitoring Boards, or DSMBs, that indicated the studies were unlikely to meet their primary endpoints. Given the news, the firm expects the shares to trade near cash value net of projected operating expenses while investors await the outcomes of the ongoing strategic review.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALVR: